855 related articles for article (PubMed ID: 32972405)
1. Targeting STAT3 in Cancer Immunotherapy.
Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
[TBL] [Abstract][Full Text] [Related]
2. The role of STAT3 in leading the crosstalk between human cancers and the immune system.
Wang Y; Shen Y; Wang S; Shen Q; Zhou X
Cancer Lett; 2018 Feb; 415():117-128. PubMed ID: 29222039
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.
Yu H; Kortylewski M; Pardoll D
Nat Rev Immunol; 2007 Jan; 7(1):41-51. PubMed ID: 17186030
[TBL] [Abstract][Full Text] [Related]
5. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
7. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Johnson DE; O'Keefe RA; Grandis JR
Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
Ko HJ; Kim YJ
Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
[TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
10. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
Yang L; Li A; Lei Q; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
[TBL] [Abstract][Full Text] [Related]
11. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
12. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
[TBL] [Abstract][Full Text] [Related]
13. Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing.
Dong Y; Chen J; Chen Y; Liu S
Biomed Pharmacother; 2023 Nov; 167():115513. PubMed ID: 37741251
[TBL] [Abstract][Full Text] [Related]
14. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
15. STAT3: A key signaling molecule for converting cold to hot tumors.
Hu R; Han Q; Zhang J
Cancer Lett; 2020 Oct; 489():29-40. PubMed ID: 32522692
[TBL] [Abstract][Full Text] [Related]
16. A TCM formula comprising Sophorae Flos and Lonicerae Japonicae Flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment.
Liu YX; Bai JX; Li T; Fu XQ; Guo H; Zhu PL; Chan YC; Chou JY; Yin CL; Li JK; Wang YP; Chen YJ; Yu ZL
Pharmacol Res; 2019 Apr; 142():115-126. PubMed ID: 30797070
[TBL] [Abstract][Full Text] [Related]
17. STAT3: a target to enhance antitumor immune response.
Lee H; Pal SK; Reckamp K; Figlin RA; Yu H
Curr Top Microbiol Immunol; 2011; 344():41-59. PubMed ID: 20517723
[TBL] [Abstract][Full Text] [Related]
18. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
Hu Y; Dong Z; Liu K
J Exp Clin Cancer Res; 2024 Jan; 43(1):23. PubMed ID: 38245798
[TBL] [Abstract][Full Text] [Related]
20. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
